NCT01181245 - A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2014

Study Completion Date

June 30, 2014

Conditions

Locally Advanced or Metastatic Pancreatic Cancer

Interventions

DRUG

FG-3019

3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly

Trial Locations (7)

University of Pennsylvania, Philadelphia

University Hospitals of Cleveland, Case Comprehensive Cancer Center, Cleveland

Virginia Mason Medical Center, Seattle

Stanford University School of Medicine, Stanford

Dartmouth Hitchcock Medical Center, Lebanon

Oregon Health Sciences University (OHSU), Portland

University of Pittsburgh, Pittsburgh